Understanding and Treating Heart Failure With Preserved Ejection Fraction: Novel Mechanisms, Diagnostics and Potential Therapeutics

N/ACompletedNCT02052804

University of Alberta700 enrolled

Overview

The objectives of this study are: 1) to design new diagnostic criteria used to accurately define heart failure with preserved ejection fraction (HFpEF); 2) to better define the risk factors associated with HFpEF; 3) to elucidate the clinical, cellular and molecular mechanisms involved with the development and progression of HFpEF; 4) to design and test new therapeutic strategies for patients with HFpEF.

Study Type

OBSERVATIONAL

Enrollment

700

Conditions

Heart Failure

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Group 1 No clinically overt heart failure * Group 2 Known coronary artery disease * Group 3 Known heart failure with preserved ejection fraction * Group 4 Known heart failure with reduced ejection fraction * Group 5 Healthy age-matched controls Exclusion Criteria: * Age \<18 years * Known malignancy with expected survival \<1 year * Pregnant or recent pregnancy \<6 months * Recent event (\<2 weeks since Acute Coronary Syndrome, Heart failure or other admission * Severe mitral or aortic stenosis

Locations (2)

University of Calgary

Calgary, Alberta, Canada

University of Alberta

Edmonton, Alberta, Canada

Outcomes

Primary Outcomes

Percent of patients meeting new diagnostic criteria for HFpEF

Time frame: Up to 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.